Page 79 - Genentech News Today

Activist investor Elliott Investment Management has taken a significant position in BioMarin Pharmaceutical Inc (NASDAQ: BMRN), engaging with the company on its strategic direction amid leadership changes and the evolving status of its 

By Svea Herbst-Bayliss NEW YORK (Reuters) - Activist investor Elliott Investment Management has built a stake in BioMarin Pharmaceutical and has been ...

07.11.2023 - Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the third quarter ended ...

Though office and lab space vacancies continue to climb, an increase in life science venture capital funding during the last quarter offers an economic bright spot within the real estate

06.11.2023 - Positive clinical data updates across multiple drug classes including antibody-drug conjugate (ADC) candidates BNT323/DB-1303, BNT325/DB-1305, CAR-T candidate BNT211, T cell therapy candidate BNT221 and mRNA cancer vaccine candidate BNT116Progress ...

Updated data from azenosertib monotherapy study with longer follow up shows 37% ORR and mPFS of 6.5 months in heavily pretreated ovarian and uterine serous carcinoma patients Azenosertib programs on...

Exelixis, Inc. (NASDAQ:EXEL) Q3 2023 Earnings Call Transcript November 1, 2023 Operator: Good day, ladies and gentlemen, and welcome to the Exelixis Third Quarter 2023 Financial Results Conference Call. My name is Gigi, and I’ll be your operator for today. As a reminder, this call is being recorded for replay purposes. I would now like […]

-- Disclosure of eIF4E, a regulator of oncoprotein translation, as target of most advanced program ---- Data demonstrate strong in vivo anti-tumor effects of orally bioavailable small molecules; IND enabling studies planned ---- Additional data to be presented at San Antonio Breast Cancer Symposium in early December...

BNTX earnings call for the period ending September 30, 2023.

Patients who are female, in minority groups (particularly, Black or Asian), a visual acuity outside of the <20/40 to 20/200 range, and who are >70 years old receive less treatment.